English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17933/22952 (78%)
Visitors : 7350985      Online Users : 177
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/15690


    Title: ZEB1 as an indicator of tumor recurrence for areca quid chewing-associated oral squamous cell carcinomas.
    Authors: CM, Ho
    FW, Hu
    SS, Lee
    TM, Shieh
    CH, Yu
    SS, Lin
    CC, Yu
    Contributors: 中山醫大口腔科學研究所
    Keywords: ZEB1;arecoline;oral squamous cell carcinoma
    Date: 2014-11-04
    Issue Date: 2016-08-09T07:56:06Z (UTC)
    ISSN: 0904-2512
    Abstract: BACKGROUND:
    Oral squamous cell carcinoma (OSCC) is the sixth most prevalent malignancy worldwide and the third most common cancer in developing nation. Most OSCC patients relapse within months after receiving treatment. Therefore, searching the biomarkers of recurrence is urgently required to improve OSCC patient survival.
    METHODS:
    We set out to explore whether expression of ZEB1 could be triggered in oral epithelial cells (SG and FaDu) by arecoline in vitro. Control and ZEB1-knockdown arecoline-stimulated SG and FaDu were subjected to migration/invasiveness/anchorage-independent growth assay. Primary and recurrent OSCC tissues from areca quid chewers were analyzed using real-time RT-PCR analysis for ZEB1 expression.
    RESULTS:
    Arecoline led to dose-dependent elevation of ZEB1 expression in SG and FaDu cells. Downregulation of ZEB1 by lentiviral infection significantly reversed arecoline-induced oncogenicity including migration ability, cell invasiveness, and anchorage-independent growth in SG and FaDu cells. Clinically, the level of ZEB1 expression was higher in recurrent OSCC tumor samples but lower in primary lesions.
    CONCLUSIONS:
    Targeting ZEB1 might offer a new strategy for the treatment of OSCC patients. ZEB1 can serve as a progression and relapse marker in OSCC patients.
    © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
    URI: http://dx.doi.org/10.1111/jop.12286
    https://ir.csmu.edu.tw:8080/ir/handle/310902500/15690
    Relation: J Oral Pathol Med. 2015 Oct;44(9):693-8.
    Appears in Collections:[牙醫學系暨碩士班] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML298View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback